发明授权
US09102631B2 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
有权
1-（芳基甲基）-5,6,7,8-四氢喹唑啉-2,4-二酮及其类似物及其用途
- 专利标题： 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
- 专利标题（中）： 1-（芳基甲基）-5,6,7,8-四氢喹唑啉-2,4-二酮及其类似物及其用途
-
申请号： US14355071申请日： 2012-11-01
-
公开(公告)号： US09102631B2公开(公告)日： 2015-08-11
- 发明人: Suixiong Cai , Ye Edward Tian , Lizhen Wu , Lijun Liu , Xiaozhu Wang , Yangzhen Jiang , Guoxiang Wang , Xiuyan Zhang , Qingbing Xu , Zheng Meng
- 申请人： Impact Therapeutics, Inc.
- 申请人地址： CN Nanjing, Jiangsu
- 专利权人： IMPACT Therapeutics, Inc.
- 当前专利权人： IMPACT Therapeutics, Inc.
- 当前专利权人地址： CN Nanjing, Jiangsu
- 代理机构： Sterne, Kessler, Goldstein & Fox P.L.L.C.
- 优先权： CN201110340698 20111101
- 国际申请： PCT/CN2012/083914 WO 20121101
- 国际公布： WO2013/064083 WO 20130510
- 主分类号： C07D239/96
- IPC分类号： C07D239/96 ; C07D401/12 ; C07D403/12 ; C07D409/12 ; C07D417/12 ; A61K31/517 ; C07D239/90 ; C07D487/04 ; C07D491/052 ; C07D495/04 ; A61K45/06 ; C07D405/12 ; C07D239/70 ; A61N5/10 ; C07D409/14
摘要：
Disclosed are novel 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs thereof, represented by the Formula 1: wherein Ar, A, R1, R3-R6 are defined herein. Compounds having Formula I are PARP inhibitors. Therefore, compounds of the invention may be used to treat clinical conditions that are responsive to the inhibition of PARP activity, such as cancer.
公开/授权文献
信息查询
